Related references
Note: Only part of the references are listed.Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
Andres Jan Schrader et al.
EUROPEAN UROLOGY (2014)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y. Loriot et al.
ANNALS OF ONCOLOGY (2013)
2012 FDA drug approvals
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
BK Matuszewski et al.
ANALYTICAL CHEMISTRY (2003)
Share Paper
